Pharma industry groups escalated legal pressure against U.S. drug pricing proposals, arguing the latest Medicare “most-favored nation” (MFN) pilot oversteps statutory authority. Separately, the EU is signaling operational changes ahead of the proposed Biotech Act, with the EMA warning that the Clinical Trials Information System will need major rebuilding to meet new authorization and supervision workflows. The developments sharpen the near-term regulatory and cost environment biotech companies face: pricing policy is moving faster through litigation, while clinical-trials infrastructure is being redesigned to support EU-wide flexibility and accelerated assessments. Together, they raise execution stakes for sponsors planning trials and market access timelines. Key actions being watched include whether courts narrow MFN’s scope and how quickly CTIS changes can be delivered on the Biotech Act timeline. Both could affect trial planning, data flow, and ultimately portfolio economics for developers operating in multiple jurisdictions.